Capricor Therapeutics Faces Securities Class Action Over Deramiocel

The complaint filed against the NASDAQ-listed firm centers on allegations that Capricor violated the Securities Exchange Act of 1934. According to the court filings, the company altered its statistical analysis plan for Deramiocel without obtaining prior FDA agreement before resubmitting its Biologics License Application. These actions form the basis for claims that the company’s public disclosures during the class period were materially misleading.

The DJS Law Group, led by David J. Schwartz, is currently seeking shareholders to serve as lead plaintiffs. While participation in the recovery does not mandate a lead plaintiff appointment, affected investors are encouraged to contact the firm to review their potential claims. The lawsuit seeks to address losses sustained by shareholders following the disclosure of these regulatory discrepancies.